Stada Claims A First With Ready-To-Use Bortezomib In Europe
Executive Summary
Stada says it is not only first-to-market with generic bortezomib in major European markets. It is also offering a more convenient ready-to-use solution.
You may also be interested in...
Stada’s Rare Kidney Disease Drug Is EU First
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.
Stada Enjoys Robust First Half For Generics And Biosimilars
With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.
Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings
Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.